Targeting cell cycle kinases for cancer therapy.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tumorigenesis is often driven by dysregulated protein kinases controlling the cell cycle.
• Cyclin-dependent kinases (CDKs) are crucial for cell proliferation and frequently altered in cancer.
• Other mitotic kinases like Aurora and Polo-like kinases (PLKs) are emerging as significant cancer targets.

Purpose of the Study:

• To review the role of cell cycle kinases in cancer.
• To discuss the therapeutic potential of targeting these kinases.
• To highlight the need for further research in optimizing cancer therapy strategies.

Main Methods:

• Literature review of studies on cell cycle kinases in cancer.
• Analysis of the roles of various kinases (CDKs, Aurora, PLKs, TTK, BUB, NEK) in cell division.
• Evaluation of current and potential therapeutic strategies targeting these kinases.

Main Results:

• Numerous small-molecule CDK inhibitors are in clinical development.
• Aurora kinases and PLK1 are recognized as important targets for cancer therapy.
• Less-studied kinases like TTK, BUB, and NEK also play critical roles in mitosis and warrant investigation.

Conclusions:

• Targeting cell cycle kinases can arrest tumor cell proliferation.
• The optimal strategy for potent and specific tumor inhibition is still under investigation.
• Further biochemical and genetic studies are essential to develop novel cancer therapies targeting these kinases.